The prognostic Meta‐analysis of the above four datasets revealed that high expression of TP73 performed as a high‐risk factor impacting the survival of WHO grade II/III glioma, with HR (95%‐CI) values were 2.09 (1.65, 2.64), 1.37 (1.20, 1.55), 1.49 (1.22, 1.82) and 2.34 (1.76, 3.12) in CGGA_325, CGGA_693, CGGA_301 mRNA array and TCGA_LGG datasets, respectively (Figure 4A). Here, TP73 is linked to central nervous system cancer.